Metagenomi Therapeutics, Inc.
MGX
$1.16
-$0.01-0.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -38.05% | 7.91% | 3.72% | -8.63% | -85.38% |
| Total Depreciation and Amortization | -5.24% | -6.11% | -11.02% | -2.93% | 1.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -22.73% | 13.15% | -64.68% | 3.82% | 35.91% |
| Change in Net Operating Assets | 133.30% | -28.09% | 59.59% | 55.11% | 61.75% |
| Cash from Operations | 8.18% | 7.30% | 10.39% | 20.22% | 19.23% |
| Capital Expenditure | 1.57% | 91.32% | 74.55% | 93.83% | 80.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 73.74% | -83.97% | 12.37% | 454.76% | 254.89% |
| Cash from Investing | 73.91% | -83.88% | 13.39% | 406.28% | 246.30% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -32.11% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 97.45% | 64.94% | -- | -- | -- |
| Cash from Financing | 140.36% | 64.94% | -- | 61.99% | 91.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 685.16% | -1,051.69% | 291.98% | 116.42% | 94.33% |